LRMR Stock Analysis: Larimar Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 333m USD | 12M Return: 6.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.29M
Qual. Beats: 1
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Larimar Therapeutics is a U.S.-based, clinical-stage biotechnology company developing treatments for rare diseases using its proprietary cell penetrating peptide (CPP) technology platform, which is designed to deliver therapeutic proteins into cells. As a clinical-stage company, Larimar has no approved products on the market and relies on external financing and continued R&D progress to advance its pipeline.
The companys lead candidate, CTI-1601, is being evaluated in a Phase 2 OLE clinical trial for Friedreichs ataxia, a rare, progressive, and fatal genetic disorder with no approved disease-modifying therapies. Targeting rare and orphan indications is a common strategy in the biotechnology sector, often supported by regulatory pathways such as Orphan Drug designation that can provide extended exclusivity and tax credits.
Larimar is headquartered in Bala Cynwyd, Pennsylvania, and trades on the Nasdaq under the ticker LRMR. Like many small-cap biotechs, its valuation is largely tied to clinical and regulatory milestones rather than current revenue.
- CTI-1601 Phase 2 OLE data readout in Friedreichs ataxia
- FDA lifts partial clinical hold on lead program
- Cash runway extension via equity offering raises dilution concerns
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.63 > 0.02 and ΔFCF/TA -11.59 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.63 > 3% & CFO -131.3m > Net Income -166.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (85.2m) vs 12m ago 33.17% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.28%; Δ -0.28% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.75 (Total Current Assets 205.0m - Total Current Liabilities 47.8m) / Total Assets 208.5m |
| B: -2.23 (Retained Earnings -464.4m / Total Assets 208.5m) |
| C: -0.88 (EBIT TTM -166.0m / Avg Total Assets 189.3m) |
| D: 3.13 (Book Value of Equity 158.0m / Total Liabilities 50.5m) |
| Altman-Z'' = -4.92 = D |
As of July 08, 2026, the stock is trading at USD 3.41 with a total of 1,741,067 shares traded. Over the past week, the price has changed by +6.56%, over one month by +10.00%, over three months by -32.34% and over the past year by +6.56%.
Current recommended Stop Loss: 2.80 (which is 17.9% or 2.3 ATR below the current price).
Larimar Therapeutics has received a consensus analysts rating of 4.91. Therefore, it is recommended to buy LRMR.
- StrongBuy: 10
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.9 | 336.7% |
P/B = 2.1068
Revenue TTM = 0.0 USD
EBIT TTM = -166.0m USD
EBITDA TTM = -165.7m USD
Long Term Debt = 2.72m USD (estimated: total debt 3.78m - short term 1.06m)
Short Term Debt = 1.06m USD (from shortTermDebt, last quarter)
Debt = 3.78m USD (from shortLongTermDebtTotal, last quarter) (leases 3.78m already included)
Net Debt = -196.6m USD (calculated: Debt 3.78m - CCE 200.4m)
Enterprise Value = 136.9m USD (333.5m + Debt 3.78m - CCE 200.4m)
Interest Coverage Ratio = unknown (Ebit TTM -166.0m / Interest Expense TTM 0.0)
EV/FCF = -1.04x (Enterprise Value 136.9m / FCF TTM -131.3m)
FCF Yield = -95.95% (FCF TTM -131.3m / Enterprise Value 136.9m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 350k) / Revenue TTM)
Tobins Q-Ratio = 0.66 (Enterprise Value 136.9m / Total Assets 208.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 3.78m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -131.1m (EBIT -166.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.29 (Total Current Assets 205.0m / Total Current Liabilities 47.8m)
Debt / Equity = 0.02 (Debt 3.78m / totalStockholderEquity, last quarter 158.0m)
Debt / EBITDA = 1.19 (negative EBITDA) (Net Debt -196.6m / EBITDA -165.7m)
Debt / FCF = 1.50 (negative FCF - burning cash) (Net Debt -196.6m / FCF TTM -131.3m)
Total Stockholder Equity = 123.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -87.67% (Net Income -166.0m / Total Assets 208.5m)
RoE = -134.1% (Net Income TTM -166.0m / Total Stockholder Equity 123.8m)
RoCE = -131.3% (out of range, set to none) (EBIT -166.0m / Capital Employed (Equity 123.8m + L.T.Debt 2.72m))
RoIC = -81.05% (negative operating profit) (NOPAT -131.1m / Invested Capital 161.8m)
WACC = 13.17% (E(333.5m)/V(337.2m) * Re(13.32%) + D(3.78m)/V(337.2m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 13.32% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 98.88 | Cagr: 34.25%
[DCF] Fair Price = unknown (Cash Flow -131.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.32 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.38 | Chg30d=+1.83% | Revisions=+25% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-0.42 | Chg30d=+2.02% | Revisions=+25% | Analysts=7
EPS current Year (2026-12-31): EPS=-1.61 | Chg30d=+0.62% | Revisions=+40% | GrowthEPS=+29.1% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.16 | Chg30d=+5.25% | Revisions=+25% | GrowthEPS=+27.8% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +62% (up=5, down=0)